JPMorgan Reinstates Stoke Therapeutics (STOK) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts STOK Hot Sheet
Price: $26.29 --0%
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 8
Rating Summary:
14 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 8
Join SI Premium – FREE
JPMorgan analyst Jessica Fye reinstates coverage on Stoke Therapeutics (NASDAQ: STOK) with a Neutral rating and a price target of $6.00.
For an analyst ratings summary and ratings history on Stoke Therapeutics click here. For more ratings news on Stoke Therapeutics click here.
Shares of Stoke Therapeutics closed at $4.22 yesterday.
You May Also Be Interested In
- Stoke Therapeutics (STOK) PT Lowered to $43 at Goldman Sachs
- TD Cowen Starts AngloGold Ashanti (AU) at Buy
- Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
